ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1582

Clinical Correlations and Expression Pattern of the Autoimmunity Susceptibility Factor Diora-1 in Primary Sjögren’s Syndrome

Lauro Meneghel1, Lara Aqrawi1,2,3, Lara Mentlein1, Albin Björk1, Gudny Ella Thorlacius1, Margarita Ivanchenko1, Jorge Ramírez1, Kathrine Skarstein2,4, Marika Kvarnström1, Susanna Brauner1, Alexander Espinosa1 and Marie Wahren-Herlenius1, 1Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 2The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, Bergen, Norway, 3Department of Oral Surgery and Oral Medicine, Institute of Clinical Odontology, University of Oslo, Oslo, Norway, Oslo, Norway, 4Department of Pathology, Haukeland University Hospital, Bergen, Bergen, Norway

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases and autoimmunity, B cells, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Genome-wide association studies of multiple autoimmune diseases, including primary Sjögren’s syndrome (pSS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have revealed an association with the chromosome 8 locus FAM167A-BLK. The disease-associated genotypes of SNPs in the locus have been linked to a significantly increased expression of FAM167A in B cells. While BLK (B lymphocyte kinase) has a well-established role in B cells, little is known about FAM167A (family with sequence similarity 167 member A). We recently cloned and investigated the gene product of FAM167A, identifying an encoded protein with high content of intrinsic disorder which we denoted Disordered Autoimmunity 1 (DIORA-1). In the present study we investigated the expression of DIORA-1 in human immune cells and in salivary glands of patients with pSS, as well as assessed DIORA-1 expression in relation to pSS clinical manifestations to begin understanding the role of DIORA-1 in rheumatic disease pathogenesis.

Methods: Primary cells were purified from peripheral blood or buffy coats by MACS beads, and cell lines representing discrete differentiation stages of B cells were cultured under standard conditions. DIORA-1 mRNA expression was assessed by qPCR. Immunohistochemistry was performed to identify DIORA-1 expressing cells in salivary gland biopsies, and characterization of the cells and DIORA-1 localization performed by immunofluorescence using double staining. Characterization of DIORA-1 expressing cells was performed by immunofluorescence. In all, 55 patients with pSS, 20 sicca patient controls and 29 healthy donors were included in the study.

Results: We observed expression of DIORA-1 in CD19+ B cells from peripheral blood, while CD3+ T cells and CD14+ monocytes expressed little or no DIORA-1. To further define the expression pattern of DIORA-1 in B cells, we analyzed cell lines representing discrete differentiation stages of B cells. Interestingly, we observed a graded expression of DIORA-1 in these various cell lines, with the highest expression found in the two plasma cell myeloma lines and intermediate expression in other B cell lines, whereas little or no expression was observed in T cells and other investigated cell lines. CD138+ plasma cells expressing DIORA-1 intracellularly were observed within the salivary glands of pSS patients. Spatially, DIORA-1+ cells were detected within the focal infiltrates and interstitially in salivary gland biopsies. Notably, expression of DIORA-1 correlated to salivary gland focus score, as well as serum IgG levels and the presence of Ro/SSA autoantibodies.

Conclusion: These findings indicate a role for DIORA-1 in select B cell subsets, and moreover suggest that DIORA-1 potentially contribute to the inflammatory process and disease pathogenesis in pSS through B cell involvement.


Disclosure: L. Meneghel, None; L. Aqrawi, None; L. Mentlein, None; A. Björk, None; G. E. Thorlacius, None; M. Ivanchenko, None; J. Ramírez, None; K. Skarstein, None; M. Kvarnström, None; S. Brauner, None; A. Espinosa, None; M. Wahren-Herlenius, None.

To cite this abstract in AMA style:

Meneghel L, Aqrawi L, Mentlein L, Björk A, Thorlacius GE, Ivanchenko M, Ramírez J, Skarstein K, Kvarnström M, Brauner S, Espinosa A, Wahren-Herlenius M. Clinical Correlations and Expression Pattern of the Autoimmunity Susceptibility Factor Diora-1 in Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-correlations-and-expression-pattern-of-the-autoimmunity-susceptibility-factor-diora-1-in-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-correlations-and-expression-pattern-of-the-autoimmunity-susceptibility-factor-diora-1-in-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology